Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...
More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results